Gynecologic Imaging Reporting and Data System (GI-RADS)

Transvaginal ultrasound is the main reference technique in the evaluation of adnexal masses. Based on the Breast Imaging Reporting and Data System (BIRADS) classification Amor et al. suggested adapting this system to gynecologic ultrasound for the evaluation of adnexal masses: Gynecologic Imaging Reporting and Data System (GI-RADS) and based on recognition patterns and criteria recommended by the IOTA group.
Continue reading

Thyroid Imaging Reporting and Data System (TI-RADS)

Thyroid nodules are a frequent finding on neck sonography. Most nodules are benign; therefore, many nodules are biopsied to identify the small number that are malignant or require surgery for a definitive diagnosis. In 2012, the ACR convened committees to (1) provide recommendations for reporting incidental thyroid nodules, (2) develop a set of standard terms (lexicon) for ultrasound reporting, and (3) propose a TI-RADS on the basis of the lexicon.
Continue reading

Prostate Imaging Reporting And Data System (PI-RADS)

PI-RADS is designed to improve focal lesion detection, localization, characterization, and risk stratification in patients with suspected cancer and consists of technical recommendation for MRI acquisition and a scoring system for image interpretation. PI-RADS uses a scale of 1–5 to report the overall probability of clinically significant prostate cancer on multiparametric MRI (mpMRI). The use of PI-RADS is limited to treatment naive patients and it should not be used for staging, assessment of treatment outcome, recurrence, or progression during surveillance.
Continue reading

Liver Imaging Reporting and Data System (LI-RADS)

The Liver Imaging Reporting and Data System (LI-RADS) standardizes the interpretation, reporting, and data collection for imaging examinations in patients at risk for hepatocellular carcinoma (HCC). It assigns category codes reflecting relative probability of HCC to imaging-detected liver observations based on major and ancillary imaging features. LI-RADS also includes imaging features suggesting malignancy other than HCC.
Continue reading

Initial Screening for Hereditary Breast and Ovarian Cancer Syndrome

The initial screening for hereditary breast and ovarian cancer syndrome should include specific questions about the patient’s personal and family history of breast and ovarian cancers, risk assessment, education, and counseling.
Continue reading

Cervical-Cancer Screening Guidelines

The incidence of cervical cancer, as well as mortality rates from the disease, has decreased over the past 30 years because of widespread screening with cervical cytology. The American College of Obstetricians and Gynecologists (ACOG) recently published a clinical management guideline on cervical cytology screening.
Continue reading

Prostate-Cancer Screening Guidelines

The rationale for screening is that early detection and treatment of asymptomatic cancers could extend life, as compared with treatment at the time of clinical diagnosis. The introduction of prostate-specific antigen (PSA) testing has nearly doubled the lifetime risk of receiving a diagnosis of prostate cancer.
Continue reading

Guidelines for the Use of Erythropoietic Proteins in Anaemic Patients with Cancer

Anaemia is a frequent finding in cancer patients and should be carefully assessed. Additional causes of anaemia such as iron deficiency, bleeding, nutritional defects or haemolysis should be corrected prior to erythropoietic protein therapy. The following recommendations are related to adult cancer patients with solid tumours or haematological malignancies:
Continue reading

Indications and Contraindications Radioiodine Treatment of Differentiated Thyroid Cancer (DTC)

Differentiated thyroid cancer (DTC) is defined as a carcinoma deriving from the follicular epithelium and retaining basic biological characteristics of healthy thyroid tissue, including expression of the sodium iodide symporter (NIS), the key cellular feature for specific iodine uptake.
Continue reading